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annual questionnaire that was specifically designed to assess the symptoms and 
problems of the disease. Results: We review our results of over 10 years of follow-
up, and discuss the survey’s contribution to the field. Tracking 408 Pompe patients 
between 2002 and 2013, the cumulative data reveals the broad range of clinical man-
ifestations that interfere with patients’ lives. The survey allowed us to quantify the 
rate of disease progression and the positive effects of ERT on patients’ quality of life, 
fatigue, and participation in daily life. Furthermore, it showed for the first time that 
survival is reduced in adult Pompe disease and improved by ERT. ConClusions: 
Our results show that a patient survey can serve as a valuable and reliable tool for 
obtaining quantifiable information on the natural course of a rare disease and on 
the effects of therapy in a large cohort over a very long time. Most importantly, by 
working with patient reported outcomes, the survey provides the data that is truly 
relevant to the patient and complementary to clinical datasets.
PSY84
The ImPacT of orThoPaedIc SurgerY on The QualITY of lIfe of 
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objeCtives: To conduct a systematic review of the literature and assess the impact 
of orthopaedic surgery on the health-related quality of life (HRQoL) of haemophilia 
patients with or without inhibitors. Methods: Searches were conducted in the 
MEDLINE, EMBASE, EconLit, Cochrane library and the Center for Reviews and 
Dissemination databases from 2000 onwards. A broad search including both Medical 
Subject Heading (MeSH) terms and key words related to haemophilia and HRQoL 
was conducted. We included only the publications reporting pre- and post-surgery 
HRQoL data and all orthopedic interventions were considered. Congress abstracts 
from 2010 were also reviewed. Abstracts and full text articles were screened by 
two reviewers and conflicts arbitrated. Results: A total of 1,471 articles were 
retrieved. Following the screening process, 8 full-text articles reporting pre- and 
post-surgery HRQoL data for patients who received ankle arthrodesis, total knee 
replacement, ankle replacement or hip arthroplasty were included. Seven studies 
used patient-reported measures and only one study estimated the EQ-5D using 
indirect matching techniques. Of the seven studies, four used the visual analogue 
scale (VAS). Three concluded that post-operative pain was significantly lower and 
only one study reported that although pain decreased post-surgery, moderate pain 
remained among patients who underwent multiple joint procedures and received 
ankle arthrodesis. Of the four studies that reported SF-36/SF-12 scores, significant 
gains in physical health scores were observed in three and higher mental health 
scores were reported in one study. Disease-specific measures, Western Ontario and 
McMaster University (WOMAC) and Oxford Knee Score, were assessed by two studies 
and improvements in pain and physical functioning were observed on both scales. 
Evidence from SF-12 summary scores suggests that the improvements in physical 
functioning are similar for patients with and without inhibitors. ConClusions: 
Orthopaedic surgery improves the HRQoL of haemophilia patients with severe 
arthropathy.
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objeCtives: When applying accepted health economic methods, it is not uncom-
mon to find valuations of patients’ health states that are worse than dead. 
Hypothetical valuations (the UK value set) of states according to the EQ-5D resulted 
in 82 of 243 possible states being valued as worse than dead. The presence of health 
states valued worse than dead risks giving rise to counter-intuitive consequences 
when incorporated in health economic analyses. The purpose of this study was 
therefor to investigate the presence of such states in an exposed population, namely 
people 65 years and older. Methods: Based on a Swedish epidemiological popu-
lation survey study directed to 10 000 persons 65 years and older the occurrence 
of states worse than dead were investigated and related to prevalence and inten-
sity of chronic pain. Results: Health states worse than dead were found in 1.8 % 
of the 6618 responders to the questionnaire. Among persons with severe chronic 
pain the prevalence was 16.7 % and among persons with moderate and no or mild 
chronic pain the prevalence of states worse than dead were 2.7 % and 0.8 % respec-
tively. Prevalence of these states clearly increased with age and female gender. Of 
women 85 years and older with severe chronic pain 38.7 % were in states worse 
than dead. ConClusions: Health states worse than dead are not rare in an elderly 
population and covariate with chronic pain, age and female gender. The prevalence 
of states worse than dead are highly dependent on the value set applied, and will 
have consequences for assessments of treatments for elderly with chronic pain. 
Based on the results of this study it should be investigated whether and to what 
extent health states worse than dead exist when using experience based valuation 
methods, which is the preferred approach in some settings/countries.
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and SSC. Average utilities for each health state were predicted from the regression 
coefficients. Utilities were also estimated using individual health state dummy 
variables in a sensitivity analysis. Results: Utilities for health states without BP 
or SSC were 0.76 for mild, 0.69 for moderate, 0.64 for marked, and 0.60 for severe. 
The utilities for states with bone symptoms were lower: 0.67 for mild+BP, 0. 68 
for mild+SSC, 0.61 for moderate+SSC, 0.56 for marked+SSC, and 0.52 severe+SSC. 
Sensitivity analysis utilities were similar but less precise and sometimes less clini-
cally plausible. ConClusions: Compared with the norm for the EQ-5D utility index 
in the UK (0.86), these utility estimates reflect the substantial quality of life impact 
of GD1, especially with skeletal complications. These utilities can be used in future 
economic evaluations of GD1 therapies to calculate quality-adjusted life years.
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objeCtives: In the past few years, a number of biological drugs to treat pemphigus 
have successfully passed through phase 2 and 3; however, none of the clinical trials 
in pemphigus has used preference-based outcome measures to generate utilities 
for economic evaluations, so far. In attempt to fill this gap, the objective of this 
study is to measure utility weights for hypothetical pemphigus vulgaris (PV) and 
foliaceus (PF) health states in a general population sample. Methods: Three health 
state profiles were developed: an uncontrolled PV, an uncontrolled PF and a treated 
pemphigus state. Health state vignettes combined a description of living with pem-
phigus including skin and mucosal symptoms, possible food avoidance, bathing/
clothing issues, and effects on work and social life. Utilities were obtained from 
a convenience sample of 106 adults using visual analogue scale (VAS, 0-10 scale) 
and time trade-off (TTO). Lead-time TTO was applied for health states considered 
worse than dead. Utilities in this study were ranging between -1 (lower anchor of 
worse than dead) and 1 (perfect health) Results: Mean VAS scores for PV, PF and 
treated pemphigus were 2.46±1.54, 3.77±1.69 and 6.35±1.60, respectively. The esti-
mated utility weights attached for the health states were as follows: PV 0.34±0.38, 
PF 0.51±0.31 and treated pemphigus 0.73±0.31. Overall 13% and 5% judged PV and 
PF as being worse than dead. For both VAS and TTO values, significant difference 
revealed between each of the three health states (p< 0.001). ConClusions: This 
study provides the first utility weights in pemphigus. Disutility associated with 
uncontrolled pemphigus was found worse than in uncontrolled psoriasis or atopic 
dermatitis. Successful treatment of pemphigus may yield significant utility gain 
(0.22-0.39). Utilities elicited in this study may be used in cost-effectiveness analysis 
of new pemphigus treatments.
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objeCtives: Treatment options for patients with hepatitis C have made tremen-
dous progress in the last 5 years. Innovative antiviral-therapies promise a huge 
reduction of burden of disease and side-effects accompanied by an increase of 
patient’s benefit. It is unclear, however, what properties generate the highest benefit 
for patients. Methods: A systematic literature search was conducted to identify 
patient-relevant outcomes . Within N= 14 semi-structured interviews the decision 
model was generated. Eight patient relevant characteristics were identified and 
described by three or six levels. For the discrete choice experiment, an experimen-
tal design (3*3+5*6) was generated using Ngene-Software. The design consisted 72 
choices, which were divided into 6 blocks. The survey was conducted in august 2014 
with computer-assisted personal interviews. Results: N= 561 hepatitis C-patients 
(58,1% male) within different treatment states participated. The preference analysis 
(random parameter logit estimation (with 95%CI)) showed a predominance for the 
attribute “sustained virological response 6 month after end of treatment”(coef.:1,108). 
A split second rank is occupied by the possible side effects “anemia”(coef.:0.396) and 
“rash”(coef.:0.372). The attributes that describe the administration of the treatment 
“number of interferon injections” (coef.:0.224) and “duration of treatment”(coef.:0.183) 
share the third place. The attributes “fatigue/exhaustion”(coef.:0.088) and “nausea/
diarrhea”(coef.:0.067) follow. Within the treatment decision of hepatitis C-patients 
the attribute “headache”(coef.:0.036) was not taken into account, as reflected by the 
lack of significance. ConClusions: In this study, the essential decision criteria 
for an optimal antiviral therapy of hepatitis C from the Hep C patients’ view were 
obtained by using a DCE. Thereby SVR is ranked highest against all patient relevant 
side effects and mode of administration characteristics. In the context of this study 
it could be demonstrated that with the help of the DCE patient-relevant properties 
can be weighted in terms of possible treatment options. The DCE stands out by a high 
degree of realism and good handling for the patient.
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objeCtives: Pompe disease is a rare, progressive lysosomal storage disorder for 
which enzyme therapy (ERT) became available in 2006. Four years earlier, the IPA/
Erasmus MC survey, an international longitudinal prospective survey, was estab-
lished to collect information on the natural course of the disease and its burden on 
patients. Methods: The survey is a collaboration between Erasmus MC University 
Medical Center and the International Pompe Association (IPA) and comprises an 
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objeCtives: Research on pain severity and health outcomes, especially health-
related quality of life (HRQoL), is often done in a specific disease area examining spe-
cific domains within HRQoL. Although important, this research says very little about 
the relationship between general pain severity (across conditions) and domains of 
HRQoL. The purpose of this study was to investigate this relationship using a large 
sample of EU patients diagnosed with pain. Methods: Data came from the 2013 
EU National Health and Wellness Survey (NHWS; n= 62,000). The NHWS is a cross-
sectional general health survey assessed yearly in the 5 EU (UK, France, Spain, Italy, 
and Germany). Those individuals who reported a diagnosis of one or more pain types 
were the focal subsample of this analysis (n= 14,459). Patients’ HRQoL was assessed 
via the SF-36 and their pain in the past week was measured on an 11 point self-
report scale from 0 “no pain” to 10 “pain as bad as you can imagine”. Results: Initial 
descriptive results showed that there were large mean differences in SF-36 domain 
scores for those with a diagnosis of pain vs. those without. The largest differences 
were observed for the bodily pain (M= 40.91 vs. 51.88, p< .001, d= 1.06), general health 
(M= 42.89 vs. 50.68, p< .001, d= .80), and role emotional (M= 43.93 vs. 51.04, p< .001, 
d= .75) scales. With regard to pain severity in the past week, the strongest correla-
tions were observed for the bodily pain (r= -.63, p< .001) and role physical (r= -.46, 
p< .001) scales. After controlling covariates, these associations still held for both the 
bodily pain (β = -.59, p< .001) and role physical scales (β = -.45, p< .001). The nature of 
the association between severity (e.g., linear, quadratic) was also examined for each 
SF-domain score. ConClusions: Results suggest that the association between 
pain severity and HRQoL is nuanced and that pain affects different domains of 
HRQoL to varying degrees.
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objeCtives: Children with GHD can experience physical symptoms and disease-
related impacts on functioning and well-being. However, no GHD-specific measures 
exist to assess these impacts. The purpose of this qualitative study was to collect 
data to support the conceptual validity of a new measure, with a patient-reported 
outcome (PRO) version for older children and an observer-reported outcome 
(ObsRO) version for parents/guardians. Methods: Focus groups and interviews 
were conducted with 39 children (aged 8–12) with GHD, 31 parents of children with 
GHD (aged 4–12) and eight clinical experts in three countries (Germany, UK, US). 
Interviews were analysed and coded using adapted grounded theory to determine 
overarching themes and concepts. Based on the analysis, a conceptual model of 
the impact of GHD was developed and items for both versions generated and then 
cognitively debriefed. Results: Qualitative analysis found the saturation of con-
cepts was reached with four domains of impact: Symptoms, Physical, Social, and 
Emotional. Sub-concepts included appetite (48%), strength (42%) and energy level 
(38%) for Symptoms; limitations in physical performance (58%) and reaching (44%) 
for Physical; mistaken for younger (58%) and teasing (41%) for Social; and worry 
(55%) and self-confidence (41%) for Emotional. Emotional impacts were often related 
to others’ perception or treatment of the child as younger. Children and parents 
reported consistent symptoms/impacts, although severity of impacts sometimes 
varied. Impacts were moderated by factors including velocity of physical growth 
and age at treatment initiation. All versions were cognitively debriefed in a new 
sample (N= 26: 13 children, 13 parents) and, based on findings, it was determined 
that the PRO version was appropriate for children aged 9–12. A 32-item TRIM-CGHD 
(PRO and ObsRO versions) was finalized. ConClusions: The conceptual validity 
of both versions of the TRIM-CGHD is supported by these qualitative findings and 
the measure is now ready for psychometric validation.
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objeCtives: To explore impact of weight loss on patient-reported outcomes in indi-
viduals without type 2 diabetes, but with obesity (BMI ≥ 30 kg/m2) or overweight (BMI 
27.0-29.9 kg/m2) with ≥ one comorbidity. Patients were randomised 2:1 to once-daily 
liraglutide 3.0 mg (n= 2487) or placebo (n= 1244) as adjunct to D&E. Methods: Impact 
of Weight on Quality of Life–Lite (IWQOL-Lite) and Short-Form 36 v2 (SF-36) question-
naires were administered in countries with validated translations (approx. 82% of 
individuals). Data are reported as estimated change at end-of-trial, derived using 
ANCOVA with LOCF; increased scores signify improvement. This post hoc analysis was 
based on categorical weight change from baseline. Results are reported for liraglutide 
3.0 mg, placebo respectively, as follows: A = weight gain; B = weight loss 0−4.9%; C = 
weight loss 5−9.9%; D = weight loss 10−14.9%; E = weight loss ≥ 15%. Results: For 
individuals in the trial overall, greater proportions treated with liraglutide 3.0 mg 
versus placebo were in the higher weight loss categories: A 7.4%, 34.3%; B 29.5%, 38.6%; 
C 30.1%, 16.6%; D 18.7%, 7.0%; and E 14.4%, 3.5%. For those completing the IWQOL-Lite 
(n= 1890 liraglutide 3.0 mg, n= 886 placebo) and SF-36 (n= 1689, n= 796 respectively), 
similar profiles were observed, with liraglutide 3.0 mg achieving higher categorical 
weight loss than placebo. Changes in IWQOL-Lite total score were lowest in the weight 
objeCtives: To cluster health status among adults with hemophilia by applying the 
hidden Markov model (HMM) to account for longitudinal changes in quality of life 
scores and to derive utility weights for each cluster. Methods: Data were obtained 
from the Hemophilia Utilization Group Studies (HUGS), a prospective, multi-center 
observational study conducted from 2005 to 2013. Demographic and clinical char-
acteristics, bleeding frequency and health-related quality of life (SF-12) at initial 
interview and 3-month follow-up visits for 2 years were collected. This analysis 
included data for 211 adults with hemophilia A or B with at least two observations. 
The HMM was adapted to generate the clusters and to fit the observation sequences, 
which consisted of SF-12 physical component scores (PCS) and mental component 
scores (MCS). Utility weights were derived using Brazier’s algorithm by mapping 
SF-12 scores to a SF-6D scale. Results: Mean age was 34.6 ±13.2 years and 59% had 
severe hemophilia. Data in four unique clusters provided the best fit with the model. 
Mean PCS were [54.2±2.5, 57.1±2.4], [50.4±6.5, 47.3±9.6], [32.4±7.7, 54.4±7.1] and MCS 
were [35.3±7.1, 36.8±8.6] from cluster 1 to cluster 4, respectively. Utility weights 
for each cluster were 0.91±0.05, 0.75±0.11, 0.65±0.11 and 0.55±0.08, respectively. At 
baseline, 49 (23%) adults were classified in cluster 1, 63 (30%) in cluster 2, 67 (32%) in 
cluster 3 and 32 (15%) in cluster 4. Being in a worse health cluster was significantly 
associated with unemployment, low household income, having severe hemophilia 
and higher BMI. The mean bleeding frequencies during a 3-month period were 
1.54±2.62, 3.01±4.91, 3.80±4.09 and 4.83±5.69 among those who were assigned to 
cluster 1 to 4, respectively (p< 0.0001). ConClusions: Health status in hemophilia 
can be described by four mutually exclusive and clinically relevant clusters, which 
provide patients’ value of health outcomes for future economic analyses.
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objeCtives: Patients with chronic pain frequently require strong opioids for pain 
relief. While most patients achieve adequate analgesia, a significant minority either 
suffers intolerable side effects and/or inadequate pain relief leading to opioid 
switching. The lack of a National Pain Care Registry does not permit a successful 
investigation in this topic. Methods: Study population included all outpatients 
with chronic pain voluntarily participating in a cloud based medical surveillance 
system. Each patient was anonymously linked through an alphanumeric code to all 
opioid prescription (Anatomical Therapeutic Chemical code N02A) in a 18-month 
period. Chronic use was defined as taking the medication for more than 90 con-
secutive days. The prevalence of chronic use was calculated as the ratio between 
the number of subjects taking the medications more than 90 days consecutively 
and the total number of subjects with at least one opioid prescription. This study 
aims to assess (a) the pattern of opioid chronic use, (b) switching of active sub-
stance. Results: Out of about 2,400 occasional users of opioids analgesics, 41 (1.7%) 
were chronic users. Women represented 70.7% of chronic users (N= 29). A total of 
37 (90.2%) chronic users switched active substance at least once during the study 
period. ConClusions: In this outpatient population, the majority of chronic users 
switched active substance at least once during the study period. These results may 
suggest that poor pain control or/and unintended side effects could be a leading 
cause of active substance switching. Otherwise, for patients with inadequate pain 
relief and intolerable opioid-related toxicity/adverse effects, a switch to an alterna-
tive opioid may be the only option for symptomatic relief. However, the evidence for 
the effectiveness of opioid switching does not appear to be established.
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objeCtives: Hemophilia is a hereditary bleeding disorder characterized by 
spontaneous and traumatic bleeding requiring regular or episodic infusion of 
clotting factor. Taking care of a child with hemophilia (CWH) is burdensome for 
caregivers. For the assessment of caregivers’ burden standardized question-
naires are needed. We developed the “Hemophilia associated Caregiver Burden 
Scale” (HEMOCABTM). Methods: Questionnaire development included: 1) item 
generation (two semi-structured focus groups with 11 caregivers, evaluation of 
existing caregiver burden scales for relevance by 16 HCPs); 2) feasibility test-
ing (cognitive interviews with 12 caregivers) and 3) pilot-testing in caregivers 
of CWH with and without inhibitors < 22 years old (psychometric analysis of 
HEMOCABTM). Results: Item generation resulted in a revised questionnaire 
containing 108 questions pertaining to 13 domains. Forty caregivers (75% moth-
ers) completed the HEMOCABTM (mean age of 39.32±8.9). The majority of CWH 
had hemophilia A (95%), inhibitors (15%), were severely affected by hemophilia 
(77.5%), and had 4.83±8.9 bleeds in the last year. Caregivers reported spending 
8.69±7.7 hours per month on infusion and 3.84±6.7 hours per month travelling to 
the hemophilia centre. Psychometric testing of the HEMOCABTM showed good 
values for reliability (Cronbach’s alpha of TOTAL score: α = .97; ‘FREQUENCY’: α = .95 
and ‘BURDEN’: α = .92) and validity (convergent, known groups). HEMOCABTM 
correlated highly with the IOF (r= -.867 for total score) and revealed signifi-
cant differences among caregivers of CWH with inhibitors vs. without in all 
domains of HEMOCABTM except for ‘school’. Caregivers reported highest bur-
den in the domains ‘perception of child’, ‘emotional stress’ and ‘financial bur-
den’. ConClusions: Based on item and scale analysis 49 items were deleted and 
the final HEMOCABTM consists of 59 items. HEMOCABTM is the first hemophilia-
specific instrument for the assessment of caregiver burden with good psychomet-
ric characteristics in terms of reliability and validity. In a next step we will examine 
the sensitivity to change of the revised HEMOCABTM.
